LCM
IRD

Legato Capital Management’s Opus Genetics IRD Stock Holding History

Legato Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,098
Closed -$33.8K – 630
2023
Q3 		$33.8K Sell
10,098
-6,358
-39% -$25.5K ﹤0.01% 542
2023
Q2 		$71.4K Hold
16,456
– – 0.01% 551
2023
Q1 		$61.7K Hold
16,456
– – 0.01% 486
2022
Q4 		$58.1K Buy
+16,456
New +$43.3K 0.01% 488

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legato Capital Management's IRD Position: Q4 2023 in Review

Legato Capital Management sold out of Opus Genetics (IRD) in Q4 2023, closing a stake of 10,098 shares — an estimated $33.8K sold.

Legato Capital Management first reported a position in IRD in Q4 2022 and held it in 4 quarters. The position peaked at $71.4K in Q2 2023. 50 funds tracked by Wall St. Rank hold IRD as of Q4 2023.

  • Legato Capital Management reported no remaining Opus Genetics position as of Q4 2023 after selling out during the quarter.
  • Legato Capital Management sold 10,098 Opus Genetics shares in Q4 2023, an estimated $33.8K.
  • Legato Capital Management first reported a position in Opus Genetics in Q4 2022 and held it in 4 quarters.
  • Legato Capital Management's Opus Genetics position peaked at $71.4K in Q2 2023.
  • 50 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2023.

Based on Legato Capital Management's 13F filing for Q4 2023, filed 16 Jan 2024.